Cancer discovery news
Our researchers are making the discoveries that defeat cancer. Read the latest findings from our world-leading research.
Visit our main news hub to read about news on new funding, our fundraising activities and much more. If you want to keep updated on our news, you can follow us on social media or sign up for our Search newsletter.
If you’re a journalist and want to find out more, you can contact our media relations team.
Prostate cancer: entering a golden age of research
Oncologists are hailing this as the ‘golden age of prostate cancer research’ after new prostate cancer drugs reached the clinic. The ICR has played a major role in developing four new drugs that have been shown as effective in later-phase trials.
BRCA-targeting drugs could treat prostate cancer, leading expert says
A pioneering cancer drug set to become the first to be approved specifically for inherited cancers could also be used much more widely to treat prostate cancer, a world-leading expert said today.
How the ICR drove the science behind pioneering cancer drug
Olaparib is set to become the first cancer drug for an inherited genetic fault. Here is the story of our crucial role in its development.
Statement in response to the European Medicines Agency's recommendation for approval of olaparib
The Institute of Cancer Research, London, is issuing the following statement from Professor Alan Ashworth, whose work underpinned the development of olaparib.
Cancer drug discovery system is broken, global summit hears
Paul Workman of the ICR calls for major changes to restock pipeline with innovative cancer treatments.
Leading cancer centre receives £10 million for state-of-the-art radiotherapy machine
The ICR and The Royal Marsden will become the first institutions in the UK to own and develop world-leading MR Linac technology.
Simple blood test can quantify drug effects on protein signals to guide cancer treatment
Taking a new cancer drug once a week could benefit patients by giving healthy tissues time to recover from the effects of treatment, as suggested by a simple blood test, according to a new clinical trial.
Student on a summer placement develops new way of visualising genetics data
A student on a short-term placement at The Institute of Cancer Research, London, has led development of a new tool to visualise and analyse complex genetics data sets.
ICR team scores 100% success in the Royal Parks Half Marathon
All 22 intrepid runners for The Institute of Cancer Research successfully completed Sunday’s gruelling 13-mile Royal Parks Half Marathon to raise vital funds for our research.
New cancer drug shows signs of promise in early-stage trial
A drug which can block the activity of a common mutation in cancer has shown promise in its first patient trial, a new study reports.
Science Writing Prize 2014 – Using crystals to cure cancer
Each year, the ICR runs a science writing competition among our scientists and students – and here is 2014’s winning piece.
ICR to collaborate with Merck Serono and Wellcome Trust to co-develop anti-cancer drugs
Merck Serono, The Institute of Cancer Research (ICR), and the Wellcome Trust, London, today announced a co-development and license agreement building on two independent research programs at both the ICR and Merck Serono to identify inhibitors of tankyrase, an enzyme of the poly (ADP-ribose) polymerase family.